A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Adavosertib (Primary)
- Indications Renal cell carcinoma; Solid tumours
- Focus Therapeutic Use
- 26 Aug 2024 Planned End Date changed from 30 Aug 2024 to 30 Aug 2025.
- 26 Aug 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Aug 2025.
- 31 Aug 2023 Planned End Date changed from 30 Aug 2023 to 30 Aug 2024.